In an exchange with readers of the New England Journal of Medicine, researchers behind a recent Victoza study revealed that the drug may be linked to a higher risk of gall bladder problems.
Victoza is one of many injectable diabetes medications targeted in a multidistrict litigation in the U.S. District Court for the Southern District of California. Along with other insulin mimetics like Byetta, Januvia, and Janumet, Victoza has been linked to increased risk of thyroid and pancreatic cancer. Plaintiffs who have filed Victoza lawsuits claim that the drug’s manufacturer, Novo Nordisk, was aware of these dangerous side effects but downplayed them or concealed them from consumers. There are currently over 750 Victoza lawsuits, Byetta lawsuits, and Januvia lawsuits pending in the federal court system.
According to the gallbladder researchers, patients in the previous weight-loss study were observed to experience gall bladder–related adverse events across all weight-loss categories. The study’s authors state that these potential gall bladder side effects are not well understood and merit more investigation.
You should speak to your doctor about any health concerns you may have. If you or someone close to you was diagnosed with thyroid or pancreatic cancer after using Victoza, Byetta, or Janumet, you should contact the pharmaceutical attorneys at Lopez McHugh to receive a free legal consultation.